Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

[1]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Weber,et al.  Recent Advances Using Anti-CTLA-4 for the Treatment of Melanoma , 2009, Cancer journal.

[3]  R. Dummer,et al.  Long-term pegylated interferon-α and its potential in the treatment of melanoma , 2009, Biologics : targets & therapy.

[4]  F. Bray,et al.  Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: Rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia , 2003, International journal of cancer.

[5]  R. Mcgarry,et al.  Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials , 2001, Melanoma research.

[6]  D. Schadendorf,et al.  Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. , 2004, European journal of cancer.

[7]  A. Hauschild,et al.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2008, The Lancet.

[8]  R. Dummer,et al.  Updated Swiss Guidelines for the Treatment and Follow-Up of Cutaneous Melanoma , 2004, Dermatology.

[9]  H. Joller-jemelka,et al.  Detection of Melanoma Relapse: First Comparative Analysis on Imaging Techniques versus S100 Protein , 2006, Dermatology.

[10]  O. Nieweg,et al.  The conundrum of follow-up: should it be abandoned? , 2006, Surgical oncology clinics of North America.

[11]  S. Verma,et al.  Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. , 2008, Cancer treatment reviews.

[12]  A. Hauschild,et al.  EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. , 2008 .

[13]  V. Sondak,et al.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Dummer,et al.  A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X‐rays , 2002, The British journal of dermatology.

[15]  C. Bartoli,et al.  Micro‐melanoma detection: a clinical study on 206 consecutive cases of pigmented skin lesions with a diameter ≤ 3 mm , 2006, The British journal of dermatology.

[16]  R. Braun,et al.  Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. , 2011, Swiss medical weekly.

[17]  A. Hauschild,et al.  Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. , 2008, Melanoma research.

[18]  R. Elashoff,et al.  Sentinel-node biopsy or nodal observation in melanoma. , 2006, The New England journal of medicine.

[19]  Jennifer J. Gibson,et al.  Multiple primary melanoma: two-year results from a population-based study. , 2006, Archives of dermatology.

[20]  Martin F. Mihm,et al.  A new American Joint Committee on Cancer staging system for cutaneous melanoma , 2000, Cancer.

[21]  J. Manola,et al.  A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma , 2004, Clinical Cancer Research.

[22]  J. Kirkwood,et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Dummer,et al.  Long-term pegylated interferon-alpha and its potential in the treatment of melanoma , 2009 .

[24]  M. Nicolson,et al.  Melanoma incidence and mortality in Scotland 1979–2003 , 2007, British Journal of Cancer.

[25]  Otto S Hoekstra,et al.  Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Hauschild,et al.  [Brief guidelines: malignant melanoma of the skin]. , 2006, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[27]  D. Schadendorf,et al.  Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Eggermont,et al.  Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial , 2005, The Lancet.